Angiogenesis in newly regenerated bone by secretomes of human mesenchymal stem cells.
10.1186/s40902-017-0106-4
- Author:
Wataru KATAGIRI
1
;
Takamasa KAWAI
;
Masashi OSUGI
;
Yukiko SUGIMURA-WAKAYAMA
;
Kohei SAKAGUCHI
;
Taku KOJIMA
;
Tadaharu KOBAYASHI
Author Information
1. Division of Reconstructive Surgery for Oral and Maxillofacial Region, Department of Tissue Regeneration and Reconstruction, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. w-kat@dent.niigata-u.ac.jp
- Publication Type:Original Article
- Keywords:
Secretome;
Conditioned medium;
Cytokine;
Mesenchymal stem cells;
Angiogenesis;
Bone
- MeSH:
Animals;
Blood Vessels;
Bone Regeneration;
Culture Media, Conditioned;
Cytokines;
Enzyme-Linked Immunosorbent Assay;
Human Umbilical Vein Endothelial Cells;
Humans*;
Immunohistochemistry;
Insulin-Like Growth Factor I;
Intercellular Signaling Peptides and Proteins;
Mesenchymal Stromal Cells*;
Osteogenesis;
Rats;
Stem Cells;
Transforming Growth Factors;
Transplants;
Vascular Endothelial Growth Factor A
- From:Maxillofacial Plastic and Reconstructive Surgery
2017;39(3):8-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: For an effective bone graft for reconstruction of the maxillofacial region, an adequate vascular network will be required to supply blood, osteoprogenitor cells, and growth factors. We previously reported that the secretomes of bone marrow-derived mesenchymal stem cells (MSC-CM) contain numerous growth factors such as insulin-like growth factor (IGF)-1, transforming growth factor (TGF)-β1, and vascular endothelial growth factor (VEGF), which can affect the cellular characteristics and behavior of regenerating bone cells. We hypothesized that angiogenesis is an important step for bone regeneration, and VEGF is one of the crucial factors in MSC-CM that would enhance its osteogenic potential. In the present study, we focused on VEGF in MSC-CM and evaluated the angiogenic and osteogenic potentials of MSC-CM for bone regeneration. METHODS: Cytokines in MSC-CM were measured by enzyme-linked immunosorbent assay (ELISA). Human umbilical vein endothelial cells (HUVECs) were cultured with MSC-CM or MSC-CM with anti-VEGF antibody (MSC-CM + anti-VEGF) for neutralization, and tube formation was evaluated. For the evaluation of bone and blood vessel formation with micro-computed tomography (micro-CT) and for the histological and immunohistochemical analyses, a rat calvarial bone defect model was used. RESULTS: The concentrations of IGF-1, VEGF, and TGF-β1 in MSC-CM were 1515.6 ± 211.8 pg/mL, 465.8 ± 108.8 pg/mL, and 339.8 ± 14.4 pg/mL, respectively. Tube formation of HUVECs, bone formation, and blood vessel formation were increased in the MSC-CM group but decreased in the MSC-CM + anti-VEGF group. Histological findings suggested that new bone formation in the entire defect was observed in the MSC-CM group although it was decreased in the MSC-CM + anti-VEGF group. Immunohistochemistry indicated that angiogenesis and migration of endogenous stem cells were much more abundant in the MSC-CM group than in the MSC-CM + anti-VEGF group. CONCLUSIONS: VEGF is considered a crucial factor in MSC-CM, and MSC-CM is proposed to be an adequate therapeutic agent for bone regeneration with angiogenesis.
